The FDA accepts Durect's (DRRX) NDA for POSIDUR (previous) and says it should complete its...

|About: Durect Corporation (DRRX)|By:, SA News Editor

The FDA accepts Durect's (DRRX) NDA for POSIDUR (previous) and says it should complete its review by February 12, 2014. The product is a non-opioid treatment option for post-surgical pain. Shares +3.46% premarket. (PR)